Deal represents significant inward investment for Scotland’s cell therapy industry.

Broadoak Asset Management has announced the important letting of ground floor space within Maxim 1 to TC BioPharm Ltd (TCB). The biotechnology company has initially leased 5,000 sq ft on a ten year lease following its announcement of a strategic collaboration with MEDINET, a Tokyo-listed immune-cell therapy company, to develop a novel treatment for various types of cancer.

Using its new Scottish base of Maxim Office Park, TCB will exclusively licence MEDINET’s innovative, proven cell therapy product to progress clinical development of the new treatment in the UK and Europe.

TCB will establish a brand new clean room, lab and administration facility which will become a Scottish hub for immuno-cell therapy research to benefit cancer patients in the UK and Europe.

Dr Michael Leek, chief executive of TCB, said: “We are one important step forward to our goal of treating cancer patients with novel cell therapy and I couldn’t be more satisfied with our new location at Maxim Office Park. We have been working closely with the Maxim team to identify the best property for our needs and I’m confident the modern space will benefit our new facility and also provide us with room to grow as our company flourishes.”

TCB’s move to Maxim Office Park represents significant inward investment for Scotland’s cell therapy industry, placing the country at the forefront of the innovative therapeutic sector. The new project was announced by the First Minister of Scotland Alex Salmond and the company has been awarded a significant amount of assistance from the Scottish Government in the form of Regional Selective Assistance (RSA), strategic input from Scottish Enterprise’s High Growth Start-Up Unit and funding of academic collaborations by Glasgow City Council.

Craig Ritchie of Broadoak said: “It’s fantastic that Maxim is able to provide TCB with exactly the right facility for its scientific research needs. With flexible open plan units and a highly modern design, the space at Maxim lends itself particularly well to laboratories, as already evidenced by SEPA who took occupation of the 58,600 sq ft Maxim 6 building last year, allowing it to incorporate a first class laboratory facility alongside its office functions.

“TCB’s partnership with MEDINET will represent a great advancement in the clinical development of its novel cancer treatment and it is an honour for the company to have chosen Maxim Office Park as its Scottish base.”